KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBITDA (2016 - 2025)

Historic EBITDA for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $35.8 million.

  • Acadia Pharmaceuticals' EBITDA rose 1299.46% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.9 million, marking a year-over-year increase of 11465.94%. This contributed to the annual value of $230.8 million for FY2024, which is 41452.32% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its EBITDA stood at $35.8 million for Q3 2025, which was up 1299.46% from $32.4 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' EBITDA peaked at $153.5 million during Q4 2024, and registered a low of -$113.0 million during Q1 2022.
  • For the 5-year period, Acadia Pharmaceuticals' EBITDA averaged around -$7.9 million, with its median value being -$15.3 million (2021).
  • In the last 5 years, Acadia Pharmaceuticals' EBITDA tumbled by 10172.54% in 2022 and then soared by 90220.61% in 2024.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' EBITDA stood at -$44.7 million in 2021, then dropped by 3.15% to -$46.1 million in 2022, then surged by 175.86% to $34.9 million in 2023, then soared by 339.28% to $153.5 million in 2024, then tumbled by 76.71% to $35.8 million in 2025.
  • Its EBITDA was $35.8 million in Q3 2025, compared to $32.4 million in Q2 2025 and $19.3 million in Q1 2025.